MRSN

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates

Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting

Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer Patients

Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path

Mersana Therapeutics Announces Initiation of UPLIFT Single-Arm Registration Strategy for UpRi in Platinum-Resistant Ovarian Cancer